Advertisement
Product › Details
Lyxumia® (Adlyxin™)
Next higher product group | lixisenatide | |
Status | 2011-11-01 registration filed | |
Organisation | Sanofi S.A. (Euronext: SAN, Nasdaq: SNY) | |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | Zealand Pharma A/S (Nasdaq: ZEAL) | |
Group | Zealand Pharma (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antidiabetic
- [1] AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]"....
- [2] Pancryos ApS. (5/24/22). "Press Release: Pancryos Announces Exclusive Global License Agreement for First in Class Macroencapsulation Device". Copenhagen....
- [3] Zealand Pharma A/S. (3/30/22). "Press Release: Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations". Copenhagen & Boston, MA....
- [4] Emisphere Technologies, Inc.. (11/6/20). "Press Release: Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion". Roseland, NJ....
- [5] Pila Pharma AB. (9/24/20). "Press Release: Pila Pharma Announces Positive Phase 2a Results in People with Type 2 Diabetes and Strengthening of the Organization". Malmö....
- [6] Zealand Pharma A/S. (9/24/19). "Press Release: Zealand Pharma Achieves Primary and All Key Secondary Endpoints in Pediatric Phase 3 Trial with Dasiglucagon for Severe Hypoglycemia". Copenhagen....
- [7] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
- [8] Gilead Sciences, Inc.. (4/12/19). "Press Release: Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH". Foster City & Bagsværd....
- [9] Follicum AB. (2/11/19). "Press Release: Follicum Selects Novel Peptide Drug Candidate for the Treatment of Diabetes and Protection of Beta Cells"....
- [10] Imcyse S.A.. (11/5/18). "Press Release: Imcyse Successfully Completes Patient Enrollment in First-in-human Phase 1B Study in Type 1 Diabetes". Liège....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top